
Zachary Dovey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3464116/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings. European Urology Oncology, 2022, 5, 187-194.	5.4	20
2	Impact of diverticular disease on prostate cancer risk among hypertensive men. Prostate Cancer and Prostatic Diseases, 2022, 25, 700-706.	3.9	1
3	Why do African–American men face higher risks for lethal prostate cancer?. Current Opinion in Urology, 2022, 32, 96-101.	1.8	8
4	Current strategies to improve erectile function in patients undergoing radical prostatectomy - postoperative scenario. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
5	Current strategies to improve erectile function in patients undergoing radical prostatectomy - preoperative scenario. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	1
6	Current strategies to improve erectile function in patients undergoing radical prostatectomy-intraoperative scenario. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 79-79.	1.6	2
7	Prostate cancer biomarkers: a practical review based on different clinical scenarios. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 297-308.	6.1	2
8	Unified model involving genomics, magnetic resonance imaging and prostateâ€specific antigen density outperforms individual coâ€variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer. Cancer Reports, 2022, 5, e1492.	1.4	3
9	Prostate MRI percentage tumor involvement or "Plâ€RADS percent―as a predictor of adverse surgical pathology. Prostate, 2022, , .	2.3	0
10	Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. Cancers, 2022, 14, 2734.	3.7	5
11	Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. Cancer Reports, 2021, 4, e1340.	1.4	13
12	A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer. Research and Reports in Urology, 2021, Volume 13, 457-472.	1.0	21
13	COVID-19 in patients with and without cancer: Examining differences in patient characteristics and outcomes. , 2021, 2, 25-32.		2
14	Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. Urologic Oncology: Seminars and Original Investigations, 2021, , .	1.6	6
15	Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists. European Urology Open Science, 2020, 20, 1-11.	0.4	10
16	Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer. Cancers, 2020, 12, 2442.	3.7	7
17	Immunotherapy in prostate cancer: current state and future perspectives. Therapeutic Advances in Urology, 2020, 12, 175628722095140.	2.0	24
18	Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Communications Biology, 2020, 3, 374.	4.4	112

#	Article	IF	CITATIONS
19	Access and socioeconomic status play an important role in outcomes for African American patients with prostate cancer. Cancer, 2020, 126, 4257-4258.	4.1	1
20	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. Urologic Clinics of North America, 2020, 47, e17-e54.	1.8	39
21	Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy. Journal of Urology, 2020, 204, 82-90.	0.4	24